«KINTARO Cells®» are multipotent bone marrow-derived mesenchymal stem cells that have the ability to differentiate into cells of various types. Unlike autologous cells derived from adipose tissue, which are taken from the patients to be transplanted back into themselves, we use allogeneic stem cells obtained from young, healthy donors in their 20s.

Autologous cells are still widely used in Japan; however, globally, the mainstream use of cell therapy has already shifted to allogeneic cells. Currently, as the only provider in Japan to introduce international ATMP standards, we are expanding our research, development, and manufacturing under the brand «KINTARO Cells®», where our products are cultured using advanced culture technology and patented manufacturing methods.

Only approximately 1 in 100,000 nucleated cells in bone marrow fluid is present as mesenchymal stem cells, making them extremely rare. Multipotent stem cells «KINTARO Cells®» are collected and extracted using advanced and uniquely proprietary biotechnology.

The highest number of bone marrow–derived mesenchymal stem cells is found in the human body at birth. Thereafter, the number decreases with age: from 100% at birth to approximately 10% at age 20, 4% during a person’s 30s, 2.5% during a person’s 50s, and about 0.5% during a person’s 80s.

«KINTARO Cells®» are multipotent stem cells obtained and cultured from bone marrow–derived mesenchymal stem cells of young, healthy donors aged 20–25. They supplement the age-related decline of stem cells in the body and, through their powerful multipotent properties, have the ability to regenerate various cells and tissues throughout the body.

As stem cells differentiate into specialized tissue cells, characteristic surface markers (glycoproteins and proteins) are expressed. Bone marrow–derived mesenchymal stem cells possess a common cellular “prototype” shared across cell types, which enables their ability to differentiate into multiple kinds of cells. Therefore, «KINTARO Cells®», cultured from young and healthy bone marrow–derived mesenchymal stem cells, present no risk of immune rejection.

The culture medium used complies with cGMP standards under the supervision of the U.S. Food and Drug Administration (FDA), ensuring a high level of safety. In addition, we have introduced the world’s most advanced standards for cell culture, manufacturing, and quality control (ATMP), positioning «KINTARO Cells®» among the limited high-quality products available worldwide.